News & Publications

News

Vuja De Sciences Announces FDA Clearance of Investigational New Drug (IND) Application for VUJ-100

Natick, MA, and Hoboken, NJ, September 24, 2024

See Press Release
HebeCell and Vuja De Sciences™ Announce Strategic Collaboration

NATICK, MASS., AND HOBOKEN, N.J. (PRWEB) APRIL 06, 2022

See Press Release
Cyclenium Pharma and Vuja De Sciences™ Announce Oncology Drug Discovery Collaboration

NATICK, MASS., AND HOBOKEN, N.J., AND MONTREAL, QUEBEC (PRWEB) JANUARY 05, 2022

See Press Release
Vuja De Sciences™ Announces Appointment of Translational Medicine and Cancer Metastasis Research Pioneer to Board of Directors

NATICK, MASS. AND HOBOKEN, N.J. (PRWEB) DECEMBER 21, 2021

See Press Release
Vuja De Sciences™ Announces the Appointment of Two New Board Members

HOBOKEN, N.J. (PRWEB) JANUARY 07, 2020

See Press Release
First-ever human health and animal health drug development collaboration to prevent cancer recurrence

WOBURN, MASS. AND HOBOKEN, N.J. (PRWEB) DECEMBER 18, 2018

See Press Release

Scientific Publications

Proteomic Assessment of Extracellular Vesicles from Canine Tissue Explants as a Pipeline to Identify Molecular Targets in Osteosarcoma: PSMD14/Rpn11 as a Proof of Principle
See Paper
Assessing a Novel 3D Assay System for Drug Screening against OS Metastasis
See Paper
Innovative Approaches in the Battle Against Cancer Recurrence: Novel Strategies to Combat Dormant Disseminated Tumor Cells
See Paper
Osteosarcoma Metastasis: An Unmet Clinical Need and Unique Drug Development Opportunity
See Paper
Improved Cancer Drug Development with Drug DISCO
See Paper